These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25290725)

  • 1. Utilization of galectin-3 in case management across the spectrum of heart failure.
    McCullough P; de Boer RA; Edelmann F; Lewis CM; Maisel AS
    Rev Cardiovasc Med; 2014; 15(3):197-207. PubMed ID: 25290725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical experience using galectin-3 in heart failure.
    McCullough PA
    Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
    McCullough PA; Olobatoke A; Vanhecke TE
    Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac and renal fibrosis in chronic cardiorenal syndromes.
    Hundae A; McCullough PA
    Nephron Clin Pract; 2014; 127(1-4):106-12. PubMed ID: 25343831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
    Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 as a Biomarker to Predict Cardiorenal Syndrome in Patients with Acute Heart Failure.
    Ozyildirim S; Dogan O; Barman HA; Tanyolaç S; Atıcı A; Enar R; Doğan SM
    Acta Cardiol Sin; 2023 Nov; 39(6):862-870. PubMed ID: 38022413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.
    Tang WH; Shrestha K; Shao Z; Borowski AG; Troughton RW; Thomas JD; Klein AL
    Am J Cardiol; 2011 Aug; 108(3):385-90. PubMed ID: 21600537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure.
    Clementy N; Garcia B; André C; Bisson A; Benhenda N; Pierre B; Bernard A; Fauchier L; Piver E; Babuty D
    PLoS One; 2018; 13(8):e0201517. PubMed ID: 30067817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF.
    Sanders-van Wijk S; Masson S; Milani V; Rickenbacher P; Gorini M; Tavazzi LT; Tobler D; Rickli H; Latini R; Brunner-La Roccaenen HP;
    Clin Chem; 2016 Apr; 62(4):605-16. PubMed ID: 26936932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
    Carrasco-Sánchez FJ; Páez-Rubio MI
    Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.
    Meijers WC; Januzzi JL; deFilippi C; Adourian AS; Shah SJ; van Veldhuisen DJ; de Boer RA
    Am Heart J; 2014 Jun; 167(6):853-60.e4. PubMed ID: 24890535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
    Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure.
    Atabakhshian R; Kazerouni F; Raygan F; Amirrasouli H; Rahimipour A; Shakeri N
    Int Cardiovasc Res J; 2014 Dec; 8(4):143-7. PubMed ID: 25614856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure.
    Lassus JP; Siirilä-Waris K; Nieminen MS; Tolonen J; Tarvasmäki T; Peuhkurinen K; Melin J; Pulkki K; Harjola VP;
    Int J Cardiol; 2013 Sep; 168(1):458-62. PubMed ID: 23073273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
    van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
    Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure.
    Miró Ò; González de la Presa B; Herrero-Puente P; Fernández Bonifacio R; Möckel M; Mueller C; Casals G; Sandalinas S; Llorens P; Martín-Sánchez FJ; Jacob J; Bedini JL; Gil V
    Biomarkers; 2017 Dec; 22(8):731-739. PubMed ID: 28406038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.
    Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J
    Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.